New hope for young cancer patients: experimental drug targets tumors
NCT ID NCT04890093
Summary
This study is testing whether a new drug called PEN-866, when combined with two standard chemotherapy drugs (vincristine and temozolomide), can help control aggressive cancers that have returned or not responded to other treatments. It is for adolescents and young adults (ages 12-39) with Ewing sarcoma or rhabdomyosarcoma. The goal is to see if this combination is safe and can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Childrens National Medical Center
Washington D.C., District of Columbia, 20010, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.